ArticleClinical case reports2026
Tacrolimus-Induced Atypical Posterior Reversible Encephalopathy Syndrome (PRES) in a Kidney Transplant Recipient: A Case Report.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a 36-year-old woman who presented with acute visual hallucinations, delusions, and dizziness 2 months after uncomplicated kidney transplantation. Brain magnetic resonance imaging (MRI) revealed T2/FLAIR hyperintensities in the dorsal pons and bilateral temporal cortices, atypical yet consistent with PRES. Tacrolimus-induced PRES was diagnosed in the absence of severe hypertension or other precipitants. Tacrolimus was discontinued and replaced with cyclosporine, with complete clinical resolution and normalization of MRI findings within 8 weeks. This case underscores the importance of prompt clinical suspicion and discontinuation of tacrolimus in transplant recipients with neuropsychiatric symptoms and supportive neuroimaging, even with atypical lesion distribution. Close therapeutic drug monitoring and rapid immunosuppressant adjustment can facilitate full recovery and prevent permanent sequelae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.